Association of germline variation with the survival of women with BRCA1/2 pathogenic variants and breast cancer

[1]  Sofia Khan,et al.  Association of germline variation with the survival of women with BRCA1/2 pathogenic variants and breast cancer. , 2020, NPJ breast cancer.

[2]  M. Sherman,et al.  Progesterone and breast cancer. , 2020, Endocrine reviews.

[3]  J. Pearson,et al.  Whole-genome sequencing reveals clinically relevant insights into the aetiology of familial breast cancers. , 2019 .

[4]  R. Koževnikovová,et al.  Estrogen Receptor Status Oppositely Modifies Breast Cancer Prognosis in BRCA1/BRCA2 Mutation Carriers Versus Non-Carriers , 2019, Cancers.

[5]  A. Whittemore,et al.  Genome-wide association study of germline variants and breast cancer-specific mortality , 2019, British Journal of Cancer.

[6]  P. Swanson,et al.  DCAF1 (VprBP): emerging physiological roles for a unique dual-service E3 ubiquitin ligase substrate receptor , 2018, Journal of molecular cell biology.

[7]  D M Parkin,et al.  Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods , 2018, International journal of cancer.

[8]  H. Chen,et al.  CtBP2 promotes proliferation and reduces drug sensitivity in non-small cell lung cancer via the Wnt/β-catenin pathway. , 2018, Neoplasma.

[9]  Yinting Mao,et al.  C-terminal binding protein‑2 mediates cisplatin chemoresistance in esophageal cancer cells via the inhibition of apoptosis. , 2018, International journal of oncology.

[10]  M. Zhang,et al.  Loss of Estrogen-Regulated MIR135A1 at 3p21.1 Promotes Tamoxifen Resistance in Breast Cancer. , 2018, Cancer research.

[11]  Li Ma,et al.  ZRANB1 Is an EZH2 Deubiquitinase and a Potential Therapeutic Target in Breast Cancer. , 2018, Cell reports.

[12]  Mitchell J. Machiela,et al.  LDassoc: an online tool for interactively exploring genome-wide association study results and prioritizing variants for functional investigation , 2018, Bioinform..

[13]  David Evans,et al.  Germline BRCA mutation and outcome in young-onset breast cancer (POSH): a prospective cohort study , 2018, The Lancet. Oncology.

[14]  T. Tot,et al.  The new TNM-based staging of breast cancer , 2018, Virchows Archiv.

[15]  M. Delgado-Rodríguez,et al.  Systematic review and meta-analysis. , 2017, Medicina intensiva.

[16]  S. Yachida,et al.  Current status of poly(ADP-ribose) polymerase inhibitors and future directions , 2017, OncoTargets and therapy.

[17]  Michael Jones,et al.  Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer , 2017, Nature Genetics.

[18]  Gary D Bader,et al.  Association analysis identifies 65 new breast cancer risk loci , 2017, Nature.

[19]  J. Wands,et al.  Endocrine sensitivity of estrogen receptor‐positive breast cancer is negatively correlated with aspartate‐β‐hydroxylase expression , 2017, Cancer science.

[20]  Bin Zhang,et al.  Oxaliplatin inhibits proliferation and migration of human hepatocellular carcinoma cells via GAS7C and the N-WASP/FAK/F-actin pathway , 2017, Acta biochimica et biophysica Sinica.

[21]  T. Roberts,et al.  Functional role of SETD2, BAP1, PARP-3 and PBRM1 candidate genes on the regulation of hTERT gene expression , 2017, Oncotarget.

[22]  W. Chung,et al.  Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers , 2017, JAMA.

[23]  M. Robson,et al.  Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation , 2017, The New England journal of medicine.

[24]  Michael J. Emanuele,et al.  VprBP/DCAF1 Regulates the Degradation and Nonproteolytic Activation of the Cell Cycle Transcription Factor FoxM1 , 2017, Molecular and Cellular Biology.

[25]  Doron Lancet,et al.  GeneHancer: genome-wide integration of enhancers and target genes in GeneCards , 2017, Database J. Biol. Databases Curation.

[26]  Ting Wang,et al.  The 3D Genome Browser: a web-based browser for visualizing 3D genome organization and long-range chromatin interactions , 2017, Genome Biology.

[27]  L. Brudin,et al.  Improved survival in metastatic breast cancer 1985-2016. , 2017, Breast.

[28]  Michael B. Stadler,et al.  The Hippo kinases LATS1 and 2 control human breast cell fate via crosstalk with ERα , 2017, Nature.

[29]  Dennis J. Hazelett,et al.  The OncoArray Consortium: A Network for Understanding the Genetic Architecture of Common Cancers , 2016, Cancer Epidemiology, Biomarkers & Prevention.

[30]  O. Olopade,et al.  Effect of BRCA germline mutations on breast cancer prognosis , 2016, Medicine.

[31]  Jia Chen,et al.  miR-135a promotes gastric cancer progression and resistance to oxaliplatin , 2016, Oncotarget.

[32]  Sofia Khan,et al.  FANCM c.5101C>T mutation associates with breast cancer survival and treatment outcome , 2016, International journal of cancer.

[33]  S. Cai,et al.  MiR-20a-5p represses multi-drug resistance in osteosarcoma by targeting the KIF26B gene , 2016, Cancer Cell International.

[34]  F. Puglisi,et al.  Do platinum salts fit all triple negative breast cancers? , 2016, Cancer treatment reviews.

[35]  Tsippi Iny Stein,et al.  The GeneCards Suite: From Gene Data Mining to Disease Genome Sequence Analyses , 2016, Current protocols in bioinformatics.

[36]  Mitchell J. Machiela,et al.  LDlink: a web-based application for exploring population-specific haplotype structure and linking correlated alleles of possible functional variants , 2015, Bioinform..

[37]  Gabor T. Marth,et al.  A global reference for human genetic variation , 2015, Nature.

[38]  E. Mardis,et al.  Development and verification of the PAM50-based Prosigna breast cancer gene signature assay , 2015, BMC Medical Genomics.

[39]  Seon-Young Kim,et al.  Ctbp2 Modulates NuRD‐Mediated Deacetylation of H3K27 and Facilitates PRC2‐Mediated H3K27me3 in Active Embryonic Stem Cell Genes During Exit from Pluripotency , 2015, Stem cells.

[40]  G. Kempermann.  Faculty Opinions recommendation of Human genomics. The Genotype-Tissue Expression (GTEx) pilot analysis: multitissue gene regulation in humans. , 2015 .

[41]  Sofia Khan,et al.  Polymorphism at 19q13.41 Predicts Breast Cancer Survival Specifically after Endocrine Therapy , 2015, Clinical Cancer Research.

[42]  Jun S. Liu,et al.  The Genotype-Tissue Expression (GTEx) pilot analysis: Multitissue gene regulation in humans , 2015, Science.

[43]  R. Gelber,et al.  Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015 , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[44]  W. Willett,et al.  Common germline polymorphisms associated with breast cancer-specific survival , 2015, Breast Cancer Research.

[45]  R. Tollenaar,et al.  Worse Breast Cancer Prognosis of BRCA1/BRCA2 Mutation Carriers: What's the Evidence? A Systematic Review with Meta-Analysis , 2015, PloS one.

[46]  P. Fasching,et al.  The SNP rs6500843 in 16p13.3 is associated with survival specifically among chemotherapy-treated breast cancer patients , 2015, Oncotarget.

[47]  Neva C. Durand,et al.  A 3D Map of the Human Genome at Kilobase Resolution Reveals Principles of Chromatin Looping , 2014, Cell.

[48]  H. Brenner,et al.  Provision of breast cancer care and survival in Germany – results from a population-based high resolution study from Saarland , 2014, BMC Cancer.

[49]  M. Clemons,et al.  Definition and consequences of locally advanced breast cancer , 2014, Current opinion in supportive and palliative care.

[50]  Nouri Neamati,et al.  VprBP has intrinsic kinase activity targeting histone H2A and represses gene transcription. , 2013, Molecular cell.

[51]  M. Peters,et al.  Systematic identification of trans eQTLs as putative drivers of known disease associations , 2013, Nature Genetics.

[52]  C. Perou,et al.  Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013 , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[53]  H. Brenner,et al.  Breast Cancer Survival in Germany: A Population-Based High Resolution Study from Saarland , 2013, PloS one.

[54]  R. Berkowitz,et al.  BRCA1 expression is epigenetically repressed in sporadic ovarian cancer cells by overexpression of C-terminal binding protein 2. , 2013, Neoplasia.

[55]  M. García-Closas,et al.  Germline variation in TP53 regulatory network genes associates with breast cancer survival and treatment outcome , 2013, International journal of cancer.

[56]  Ellen T. Gelfand,et al.  The Genotype-Tissue Expression (GTEx) project , 2013, Nature Genetics.

[57]  Y. Tamaki,et al.  Clinicopathological analysis of GATA3-positive breast cancers with special reference to response to neoadjuvant chemotherapy. , 2012 .

[58]  D. Noh,et al.  EZH2 generates a methyl degron that is recognized by the DCAF1/DDB1/CUL4 E3 ubiquitin ligase complex. , 2012, Molecular cell.

[59]  Data production leads,et al.  An integrated encyclopedia of DNA elements in the human genome , 2012 .

[60]  Eurie L. Hong,et al.  Annotation of functional variation in personal genomes using RegulomeDB , 2012, Genome research.

[61]  K. Czene,et al.  Breast cancer prognosis is inherited independently of patient, tumor and treatment characteristics , 2012, International journal of cancer.

[62]  F. Markowetz,et al.  The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups , 2012, Nature.

[63]  Päivi Heikkilä,et al.  Pathology of Breast and Ovarian Cancers among BRCA1 and BRCA2 Mutation Carriers: Results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA) , 2011, Cancer Epidemiology, Biomarkers & Prevention.

[64]  Lothar Hennighausen,et al.  EZH2 Methyltransferase and H3K27 Methylation in Breast Cancer , 2011, International journal of biological sciences.

[65]  C. Chao,et al.  Knockdown of growth‐arrest‐specific gene 7b (gas7b) using short‐hairpin RNA desensitizes neuroblastoma cells to cisplatin: Implications for preventing apoptosis of neurons , 2010, Journal of neuroscience research.

[66]  Z. Szallasi,et al.  An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients , 2010, Breast Cancer Research and Treatment.

[67]  Wolfgang Viechtbauer,et al.  Conducting Meta-Analyses in R with the metafor Package , 2010 .

[68]  H. Nevanlinna,et al.  The Breast Cancer Susceptibility Mutation PALB2 1592delT Is Associated with an Aggressive Tumor Phenotype , 2009, Clinical Cancer Research.

[69]  A. Nobel,et al.  Supervised risk predictor of breast cancer based on intrinsic subtypes. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[70]  Päivi Heikkilä,et al.  NAD(P)H:quinone oxidoreductase 1 NQO1*2 genotype (P187S) is a strong prognostic and predictive factor in breast cancer , 2008, Nature Genetics.

[71]  Jing Hua Zhao,et al.  gap: Genetic Analysis Package , 2007 .

[72]  K. Czene,et al.  Familial concordance in cancer survival: a Swedish population-based study. , 2007, The Lancet. Oncology.

[73]  Jon Wakefield,et al.  A Bayesian measure of the probability of false discovery in genetic epidemiology studies. , 2007, American journal of human genetics.

[74]  K. Czene,et al.  Is breast cancer prognosis inherited? , 2007, Breast Cancer Research.

[75]  A. Hartman,et al.  The ethics of CYP2D6 testing for patients considering tamoxifen , 2007, Breast Cancer Research.

[76]  H. Nevanlinna,et al.  Relationship of patients' age to histopathological features of breast tumours in BRCA1 and BRCA2 and mutation-negative breast cancer families , 2005, Breast Cancer Research.

[77]  Barbara J. Trask,et al.  Array Comparative Genomic Hybridization Analysis of Genomic Alterations in Breast Cancer Subtypes , 2004, Cancer Research.

[78]  R. Gray.  Modeling Survival Data: Extending the Cox Model , 2002 .

[79]  E. Maher,et al.  Chromosome 3p allele loss in early invasive breast cancer: detailed mapping and association with clinicopathological features , 2001, Molecular pathology : MP.

[80]  J. Minna,et al.  High-resolution chromosome 3p allelotyping of breast carcinomas and precursor lesions demonstrates frequent loss of heterozygosity and a discontinuous pattern of allele loss. , 2001, The American journal of pathology.

[81]  P. Grambsch,et al.  Modeling Survival Data: Extending the Cox Model , 2000 .

[82]  W. Cutler,et al.  Wellness in women after 40 years of age: the role of sex hormones and pheromones. , 1998, Disease-a-month : DM.

[83]  I. Ellis,et al.  Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. , 2002, Histopathology.

[84]  R Core Team,et al.  R: A language and environment for statistical computing. , 2014 .

[85]  R. Berkowitz,et al.  BRCA 1 Expression Is Epigenetically Repressed in Sporadic Ovarian Cancer Cells by Overexpression of C-Terminal Binding Protein 21 , 2 , 2013 .

[86]  B. Carter.  Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA) , 2013 .

[87]  R. Nussbaum,et al.  Pathology of Breast andOvarian Cancers among BRCA 1 and BRCA 2 Mutation Carriers : Results from the Consortium of Investigators of Modi fi ers of BRCA 1 / 2 ( CIMBA ) , 2011 .

[88]  V. Preedy,et al.  Prospective Cohort Study , 2010 .

[89]  Y. Benjamini,et al.  Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .

[90]  P. Grambsch,et al.  A Package for Survival Analysis in S , 1994 .

[91]  D. Cox.  Regression Models and Life-Tables , 1972 .